Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization Classification

George J. Netto; Mahul B. Amin; Eva M. Compérat; Anthony J. Gill; Arndt Hartmann; Holger Moch; Santosh Menon; Maria R. Raspollini; Mark A. Rubin; John R. Srigley; Puay Hoon Tan; Satish K. Tickoo; Toyonori Tsuzuki; Samra Turajlic; Ian Cree; Daniel M. Berney

doi:10.1016/j.eururo.2022.09.015

Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization Classification

George J. Netto, Mahul B. Amin, Eva M. Compérat, Anthony J. Gill, Arndt Hartmann, Holger Moch, Santosh Menon, Maria R. Raspollini, Mark A. Rubin, John R. Srigley, Puay Hoon Tan, Satish K. Tickoo, Toyonori Tsuzuki, Samra Turajlic, Ian Cree, Daniel M. Berney

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

The Gleason system forms the basis for prostate cancer grading worldwide. It has been modified on several occasions, most recently after the International Society of Urological Pathology (ISUP) consensus conferences in 2005, 2014, and 2019, and the 2019 white paper by the Genitourinary Pathology Society. At the 2014 ISUP conference the concept of grade groups (GG1–GG5) was introduced, also referred to as ISUP grade, World Health Organization [WHO] grade, or simply grade groups. Grade groups are based on Gleason scores and have some advantages with respect to communication of results to patients, clinicians, and researchers. Grade groups offer the advantage of appropriately assigning the lowest rank (GG1) to Gleason score (GS) 3 + 3 = 6 cancers to emphasize their generally low risk in the proper clinical context (eg, prostate-specific antigen [PSA] <10 ng/ml and clinical stage ≤cT2a).

Original language	English
Pages (from-to)	301-303
Number of pages	3
Journal	European Urology
Volume	83
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2022.09.015
Publication status	Published - Apr 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2022.09.015

Cite this

Netto, G. J., Amin, M. B., Compérat, E. M., Gill, A. J., Hartmann, A., Moch, H., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., Hoon Tan, P., Tickoo, S. K., Tsuzuki, T., Turajlic, S., Cree, I., & Berney, D. M. (2023). Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization Classification. European Urology, 83(4), 301-303. https://doi.org/10.1016/j.eururo.2022.09.015

@article{32cfd934119d4d5c9bf803e0639f6f04,

title = "Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization Classification",

abstract = "The Gleason system forms the basis for prostate cancer grading worldwide. It has been modified on several occasions, most recently after the International Society of Urological Pathology (ISUP) consensus conferences in 2005, 2014, and 2019, and the 2019 white paper by the Genitourinary Pathology Society. At the 2014 ISUP conference the concept of grade groups (GG1–GG5) was introduced, also referred to as ISUP grade, World Health Organization [WHO] grade, or simply grade groups. Grade groups are based on Gleason scores and have some advantages with respect to communication of results to patients, clinicians, and researchers. Grade groups offer the advantage of appropriately assigning the lowest rank (GG1) to Gleason score (GS) 3 + 3 = 6 cancers to emphasize their generally low risk in the proper clinical context (eg, prostate-specific antigen [PSA] <10 ng/ml and clinical stage ≤cT2a).",

author = "Netto, {George J.} and Amin, {Mahul B.} and Comp{\'e}rat, {Eva M.} and Gill, {Anthony J.} and Arndt Hartmann and Holger Moch and Santosh Menon and Raspollini, {Maria R.} and Rubin, {Mark A.} and Srigley, {John R.} and {Hoon Tan}, Puay and Tickoo, {Satish K.} and Toyonori Tsuzuki and Samra Turajlic and Ian Cree and Berney, {Daniel M.}",

year = "2023",

month = apr,

doi = "10.1016/j.eururo.2022.09.015",

language = "English",

volume = "83",

pages = "301--303",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "4",

}

Netto, GJ, Amin, MB, Compérat, EM, Gill, AJ, Hartmann, A, Moch, H, Menon, S, Raspollini, MR, Rubin, MA, Srigley, JR, Hoon Tan, P, Tickoo, SK, Tsuzuki, T, Turajlic, S, Cree, I & Berney, DM 2023, 'Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization Classification', European Urology, vol. 83, no. 4, pp. 301-303. https://doi.org/10.1016/j.eururo.2022.09.015

TY - JOUR

T1 - Prostate adenocarcinoma grade group 1

T2 - rationale for retaining a cancer label in the 2022 World Health Organization Classification

AU - Netto, George J.

AU - Amin, Mahul B.

AU - Compérat, Eva M.

AU - Gill, Anthony J.

AU - Hartmann, Arndt

AU - Moch, Holger

AU - Menon, Santosh

AU - Raspollini, Maria R.

AU - Rubin, Mark A.

AU - Srigley, John R.

AU - Hoon Tan, Puay

AU - Tickoo, Satish K.

AU - Tsuzuki, Toyonori

AU - Turajlic, Samra

AU - Cree, Ian

AU - Berney, Daniel M.

PY - 2023/4

Y1 - 2023/4

N2 - The Gleason system forms the basis for prostate cancer grading worldwide. It has been modified on several occasions, most recently after the International Society of Urological Pathology (ISUP) consensus conferences in 2005, 2014, and 2019, and the 2019 white paper by the Genitourinary Pathology Society. At the 2014 ISUP conference the concept of grade groups (GG1–GG5) was introduced, also referred to as ISUP grade, World Health Organization [WHO] grade, or simply grade groups. Grade groups are based on Gleason scores and have some advantages with respect to communication of results to patients, clinicians, and researchers. Grade groups offer the advantage of appropriately assigning the lowest rank (GG1) to Gleason score (GS) 3 + 3 = 6 cancers to emphasize their generally low risk in the proper clinical context (eg, prostate-specific antigen [PSA] <10 ng/ml and clinical stage ≤cT2a).

AB - The Gleason system forms the basis for prostate cancer grading worldwide. It has been modified on several occasions, most recently after the International Society of Urological Pathology (ISUP) consensus conferences in 2005, 2014, and 2019, and the 2019 white paper by the Genitourinary Pathology Society. At the 2014 ISUP conference the concept of grade groups (GG1–GG5) was introduced, also referred to as ISUP grade, World Health Organization [WHO] grade, or simply grade groups. Grade groups are based on Gleason scores and have some advantages with respect to communication of results to patients, clinicians, and researchers. Grade groups offer the advantage of appropriately assigning the lowest rank (GG1) to Gleason score (GS) 3 + 3 = 6 cancers to emphasize their generally low risk in the proper clinical context (eg, prostate-specific antigen [PSA] <10 ng/ml and clinical stage ≤cT2a).

UR - http://www.scopus.com/inward/record.url?scp=85139188504&partnerID=8YFLogxK

UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1016/j.eururo.2022.09.015

U2 - 10.1016/j.eururo.2022.09.015

DO - 10.1016/j.eururo.2022.09.015

M3 - Article

C2 - 36202687

AN - SCOPUS:85139188504

SN - 0302-2838

VL - 83

SP - 301

EP - 303

JO - European Urology

JF - European Urology

IS - 4

ER -

Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization Classification

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this